---
title: "RAAS Blood Products Starts Phase Two Trials for SR604 Injection"
date: "2025-02-14 12:19:13"
summary: "Shanghai RAAS Blood Products said its SR604 injection entered phase two clinical trials for patients with hemophilia A/B and congenital factor VII deficiency. Part A of the trial will test single-dose safety, tolerance, and pharmacokinetics, while Part B will evaluate the drug's efficacy, pharmacokinetics, and safety over multiple doses, according..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Shanghai RAAS Blood Products said its SR604 injection entered phase two clinical trials for patients with hemophilia A/B and congenital factor VII deficiency.

Part A of the trial will test single-dose safety, tolerance, and pharmacokinetics, while Part B will evaluate the drug's efficacy, pharmacokinetics, and safety over multiple doses, according to a Friday filing with the Shenzhen bourse.

Shares of the blood products maker rose 1% in recent trade.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250213:G2467754:0/)
